Product
CHIKV VLP
Aliases
CHIKV VLP/adjuvant
4 clinical trials
2 indications
Indication
Chikungunya VirusIndication
ChikungunyaClinical trial
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and AdolescentsStatus: Completed, Estimated PCD: 2023-04-03
Clinical trial
A Phase 3 Safety and Immunogenicity Trial of the VLP-Based Chikungunya Virus Vaccine PXVX0317 in Adults ≥65 Years of AgeStatus: Completed, Estimated PCD: 2023-06-19
Clinical trial
A Phase 2 Parallel-Group, Randomized, Double-Blind Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV-VLP], Unadjuvanted or Alum-adjuvanted)Status: Completed, Estimated PCD: 2020-09-14
Clinical trial
A Phase 2 Open-Label Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV VLP], Aluminum Hydroxide Adjuvanted)Status: Completed, Estimated PCD: 2022-05-05